As of Jun 26
| -0.0101 / -2.73%|
The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 2.00. The median estimate represents a +733.56% increase from the last price of 0.36.
The current consensus among 3 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.